|
GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
MX373121B
(es)
|
2010-05-14 |
2020-04-30 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
US9301962B2
(en)
|
2010-05-14 |
2016-04-05 |
Baylor College Of Medicine |
Male contraceptive compositions and methods of use
|
|
MX384074B
(es)
|
2010-05-14 |
2025-03-12 |
Dana Farber Cancer Inst Inc |
Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
EP2705039B1
(en)
|
2011-05-04 |
2017-07-26 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
US9328117B2
(en)
|
2011-06-17 |
2016-05-03 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
EP2838881B1
(en)
|
2012-04-20 |
2018-08-08 |
AbbVie Inc. |
Isoindolone derivatives
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
US9624244B2
(en)
|
2012-06-06 |
2017-04-18 |
Constellation Pharmaceuticals, Inc. |
Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
WO2013185284A1
(en)
|
2012-06-12 |
2013-12-19 |
Abbott Laboratories |
Pyridinone and pyridazinone derivatives
|
|
EP2861255B1
(en)
|
2012-06-19 |
2019-10-09 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
US9271978B2
(en)
|
2012-12-21 |
2016-03-01 |
Zenith Epigenetics Corp. |
Heterocyclic compounds as bromodomain inhibitors
|
|
JP6401773B2
(ja)
|
2013-03-11 |
2018-10-10 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
|
|
WO2014159837A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Convergene Llc |
Methods and compositions for inhibition of bromodomain-containing proteins
|
|
ES2704048T3
(es)
*
|
2013-03-14 |
2019-03-14 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
|
|
JP6280573B2
(ja)
|
2013-03-14 |
2018-02-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
ブロモドメイン阻害薬としてのフロピリジン
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
US9227985B2
(en)
|
2013-03-15 |
2016-01-05 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
WO2014173241A1
(en)
|
2013-04-26 |
2014-10-30 |
Beigene, Ltd. |
Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
SG11201510409QA
(en)
*
|
2013-06-21 |
2016-01-28 |
Zenith Epigenetics Corp |
Novel bicyclic bromodomain inhibitors
|
|
WO2015004533A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
|
PE20160540A1
(es)
*
|
2013-06-28 |
2016-06-11 |
Abbvie Inc |
Inhibidores de bromodominios
|
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
WO2015013635A2
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
|
AU2014298051B2
(en)
|
2013-07-31 |
2018-11-15 |
Zenith Epigenetics Ltd. |
Novel quinazolinones as bromodomain inhibitors
|
|
DK3290407T3
(da)
*
|
2013-10-18 |
2020-03-23 |
Celgene Quanticel Res Inc |
Bromodomæneinhibitorer
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
WO2015074081A1
(en)
|
2013-11-18 |
2015-05-21 |
Bair Kenneth W |
Benzopiperazine compositions as bet bromodomain inhibitors
|
|
PT3071203T
(pt)
*
|
2013-11-18 |
2021-03-11 |
Forma Therapeutics Inc |
Composições de tetra-hidroquinolina como inibidores de bromodomínio bet
|
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
JP6480944B2
(ja)
*
|
2014-01-09 |
2019-03-13 |
オリオン コーポレーション |
ブロモドメイン阻害剤としての二環式複素環誘導体
|
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
EP3099677A4
(en)
|
2014-01-31 |
2017-07-26 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
JP2017504650A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
JP2017511801A
(ja)
|
2014-02-28 |
2017-04-27 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
|
|
KR20160130778A
(ko)
|
2014-02-28 |
2016-11-14 |
텐샤 세러퓨틱스 인코포레이티드 |
고인슐린혈증과 관련된 질환의 치료
|
|
MY180775A
(en)
|
2014-04-23 |
2020-12-09 |
Incyte Corp |
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
|
|
PL3157928T3
(pl)
|
2014-06-20 |
2019-07-31 |
Constellation Pharmaceuticals, Inc. |
Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
|
|
MX2017001757A
(es)
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Derivados de dihidropteridinona y sus usos.
|
|
EP3177626A4
(en)
|
2014-08-08 |
2017-12-27 |
Dana Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
TR201820050T4
(tr)
*
|
2014-09-12 |
2019-01-21 |
Glaxosmithkline Ip No 2 Ltd |
Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
|
|
US9527864B2
(en)
|
2014-09-15 |
2016-12-27 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
AU2015339511B2
(en)
|
2014-10-27 |
2020-05-14 |
Tensha Therapeutics, Inc. |
Bromodomain inhibitors
|
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
|
CN107207474B
(zh)
|
2014-12-11 |
2021-05-07 |
恒翼生物医药科技(上海)有限公司 |
被取代的杂环作为溴结构域抑制剂
|
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
|
US10307407B2
(en)
|
2015-02-27 |
2019-06-04 |
The Regents Of The University Of Michigan |
9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
|
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
GB201504694D0
(en)
*
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
BR112017028178A2
(en)
|
2015-06-26 |
2018-08-28 |
Tensha Therapeutics, Inc. |
nut midline carcinoma treatment
|
|
KR20180035905A
(ko)
|
2015-08-10 |
2018-04-06 |
다나-파버 캔서 인스티튜트 인크. |
Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
|
|
UY36875A
(es)
|
2015-09-02 |
2017-03-31 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
|
|
UA123946C2
(uk)
|
2015-09-11 |
2021-06-30 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
|
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
CA2998545A1
(en)
|
2015-09-22 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
|
WO2017060180A1
(en)
|
2015-10-05 |
2017-04-13 |
Glaxosmithkline Intellectual Property (No.2) Limited |
2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
CA3003288A1
(en)
|
2015-11-25 |
2017-06-01 |
Dana-Farber Cancer Institute, Inc. |
Bivalent bromodomain inhibitors and uses thereof
|
|
JP6967522B2
(ja)
|
2016-02-15 |
2021-11-17 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体
|
|
JP7037500B2
(ja)
|
2016-04-06 |
2022-03-16 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
Ｍｄｍ２タンパク質分解剤
|
|
AU2017246453A1
(en)
|
2016-04-06 |
2018-11-08 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
CN108884070B
(zh)
|
2016-04-07 |
2021-07-02 |
葛兰素史克知识产权第二有限公司 |
作为溴结构域抑制剂的吡啶基衍生物
|
|
RU2018133500A
(ru)
|
2016-04-07 |
2020-05-12 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Бензо[B]фураны в качестве ингибиторов бромодомена
|
|
AU2017250076B2
(en)
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
|
ES2793239T3
(es)
|
2016-04-15 |
2020-11-13 |
Abbvie Inc |
Inhibidores del bromodominio
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CA3023765A1
(en)
|
2016-05-24 |
2017-11-30 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
|
KR102643344B1
(ko)
|
2016-06-20 |
2024-03-07 |
인사이트 코포레이션 |
Bet 저해제의 결정질 고체 형태
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
CN110062759B
(zh)
|
2016-09-13 |
2022-05-24 |
密执安大学评议会 |
作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
|
|
ES2857743T3
(es)
|
2016-09-13 |
2021-09-29 |
Univ Michigan Regents |
1,4-diazepinas fusionadas como degradadores de proteína BET
|
|
EP3528810A4
(en)
*
|
2016-10-20 |
2020-06-17 |
Celgene Quanticel Research, Inc. |
BROMDOMAIN INHIBITOR
|
|
WO2018111805A1
(en)
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
US11046709B2
(en)
|
2017-02-03 |
2021-06-29 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET bromodomain inhibitors
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
US11267822B2
(en)
|
2017-09-13 |
2022-03-08 |
The Regents Of The University Of Michigan |
BET bromodomain protein degraders with cleavable linkers
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
TWI882964B
(zh)
|
2018-09-13 |
2025-05-11 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
|
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
治療前列腺癌之組合療法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
JP2025514712A
(ja)
|
2022-04-19 |
2025-05-09 |
ヌエヴォリューション・アクティーゼルスカブ |
ブロモドメインに対して活性な化合物
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|